Table 2.
Association of subclinical atherosclerosis with presence of plasma CMV DNA, and antibodies to HSV-1, HSV-2 and HHV-8 in HIV-infected men who have sex with men.
| Herpesvirusa | Unadjusted odds ratio (95% confidence interval) |
Adjusted odds ratio (95% confidence interval) | ||
|---|---|---|---|---|
|
|
||||
| Model 1b | Model 2c | Full model d | ||
| HSV-1 | 1.36 (0.81,2.26) | 1.17 (0.60, 2.26) | 1.65 (0.80,3.39) | 1.99 (0.85,4.68) |
| HSV-2 | 2.84 (1.53,5.26) | 3.04 (1.38,6.71) | 3.04 (1.22, 6.92) | 4.12 (1.58, 10.85) |
| HHV-8 | 1.30 (0.81, 2.11) | 1.04 (0.57, 1.91) | 0.86 (0.45, 1.64) | 0.99 (0.45, 2.18) |
| CMV | 0.91 (0.81, 2.11) | 0.84 (0.29, 2.43) | 0.80 (0.27, 2.40) | 0.87 (0.24, 3.12) |
Equivocal HSV-1 and HSV-2 results for 9 subjects (3%) were recorded as missing. Equivocal HHV-8 results for 6 subjects (1%) were recorded as missing. 5% (14) of samples that failed internal controls twice for CMV DNA test were coded as missing.
Model 1 controlled for age, race/ethnicity, cumulative cigarette pack-years (0 for non-smokers), alcohol consumption, cholesterol-lowering medication use, median BMI between herpesvirus test visit and CT visit, history of hypertension, history of diabetes, and family history of premature heart attack.
Model 2 controlled for all variables in Model 1 and further controlled for the other three herpesviruses.
Full model controlled for all variables in Model 2 and further controlled for HIV-1 infection duration, AIDS status, nadir CD4 T-cell, peak viral load, and history of HAART use (type, duration, and adherence).